Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

New England Journal of Medicine

Volumn 340, Issue 4, 1999, Pages 265-271

  Turrisi III, Andrew T ^a,h   Kim, Kyungmann ^b   Blum, Ronald ^c   Sause, William T ^d   Livingston, Robert B ^e   Komaki, Ritsuko ⁱ   Wagner, Henry ^f   Aisner, Seena ^g   Johnson, David H ⁱ  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c ST VINCENT S HOSPITAL   (United States)

^d LDS HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; ESOPHAGITIS; FEMALE; FEVER; HUMAN; INFECTION; LUNG SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; TREATMENT FAILURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 0033611522     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901283400403     Document Type: Article

References (32)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1992. CA Cancer J Clin 1992;42:19-38.
2. Pignon J-P, Arriagada R, Ihde D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
3. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemother apy sensitivity of established cell lines of human small cell lung cancer and its large cell morphologic variants. Cancer Res 1983;43:2806-11.
4. Turrisi AT, Glover DJ, Mason B, Alavi J, Fox K. Concurrent twice-daily multi-field radiotherapy (2X/D XRT) and platinum-etoposide chemotherapy (P/E) for limited small cell lung cancer (LSCLC): update 1987 Proc Am Soc Clin Oncol 1987;6:172. abstract.
5. Frytak S, Shaw E, Eagan R, et al. Accelerated hyperfractionated split course thoracic radiotherapy and infusion cisplatin based chemotherapy for small-cell lung cancer. Lung Cancer 1991;7:Suppl:157.
6. Johnson BE, Salem C, Nesbitt J, et al. Limited stage small-cell lung cancer (SCLC) treated with concurrent BID chest radiotherapy (RT) and etoposide/cisplatin (VP/Pt) followed by chemotherapy (CT) selected by in vitro drug sensitivity testing (DST). Proc Am Soc Clin Oncol 1991;10: 240. abstract.
7. Johnson DH, Turrisi AT, Chang AY, et al. Alternating chemotherapy and twice daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 1993;11:879-84.
8. Shank B, Scher H, Hilaris BS, Pinsky C, Martin M, Wittes RE. Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung. Cancer 1985;56:2771-8.
9. McCracken JD, Janaki LM, Crowley JJ, et al. Concurrent chemotherapy/ radiotherapy for limited small-cell lung carcinoma: a Southwestern Oncology Group study. J Clin Oncol 1990;8:892-8.
10. Common toxicity criteria. Vol. 2.0. Bethesda, Md.: National Cancer Institute, March 1998.
11. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small-cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1998; 33:1752-8.
12. Komaki R, Byhardt RW, Anderson T, et al. What is the lowest effective biologic dose for prophylactic cranial irradiation? Am J Clin Oncol 1985; 8:523-7.
13. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974;27:365-75.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete ob servations. J Am Stat Assoc 1958;53:457-81.
15. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952;47:583-621.
16. Cox DR, Snell EJ. Analysis of binary data. 2nd ed. London: Chapman & Hall, 1989.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
18. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972-34: 187-220.
19. Arriagada R, Le Chevalier T, Pignon J-P, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-52.
20. Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632-41. [Erratum J Clin Oncol 1995;13:2860.]
21. Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group study. J Clin Oncol 1997;15:2840-9.
22. LeBeau B, Chastang C, Urban T, et al. A randomized clinical trial comparing concurrent and alternated thoracic irradiation in limited small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1996;15:383. abstract.
23. Murray N, Coy P, Pater JL, et al. The importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993;11:336-44.
24. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or with out radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-8.
25. Sierocki JS, Hilaris BS, Hopfan S, et al. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979;63:1593-7.
26. Natale RB, Wittes RE. Combination cis-platinum and etoposide in small cell lung cancer. Cancer Treat Rev 1982;9:Suppl:91-4.
27. Perez CA, Einhorn LH, Oldham RK, et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 1984;2:1200-8.
28. Greco FA, Brereton HD, Kent H, Zimbler H, Merrill J, Johnson RE. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976;85:294-8.
29. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective randomized trial. Ann Intern Med 1987;106:655-62.
30. Choi NC, Herndon JE II, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. I Clin Oncol 1998; 16:3528-36.
31. Papac RJ, Son Y, Bien R, Tiedemann D, Keohane M, Yesner R. Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy. Int J Radiat Oncol Biol Phys 1987;13:993-8. [Erratum, Int J Radiat Oncol Biol Phys 1988;14:213.]
32. Takada M, Fukuoka M, Furuse K, et al. Phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with cisplatin (C) and etoposide (E) for limited stage (LS) small-cell lung cancer (SCLC): preliminary results of the Japan Clinical Oncology Group (JCOG). Proc Am Soc Clin Oncol 1996;15:372. abstract.